CAR-T Meeting 2024 | EHA/EBMT Consensus Grading of ICAHT
Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly outlines the EHA/EBMT Consensus Grading of immune effector cell-associated hematotoxicity (ICAHT). As there were high levels of heterogeneity in the grading and management of ICAHT, this grading system was developed to distinguish between patients with early and late ICAHT. Dr Rejeski anticipates that this will allow for severity-based treatment recommendations to be made. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS/CELGENE
Honoraria: BMS/CELGENE, Novartis
Travel Support: Kite/Gilead, Pierre-Fabre
Research Funding: Kite/Gilead
